loader2
Partner With Us NRI

Mankind Pharma Ltd share Price Today

Company details

2,100.00
2,141.95
1,320.00
2,490.00
6M Return 10.48%
1Y Return 54.54%
Mkt Cap.(Cr) 84,662.27
Volume 595,037
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 595,037

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Mankind Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from Operations at Rs 2,441 crore, up by 19% YoY
  • Domestic revenue at Rs 2,174 crore, up 10% YoY; Exports at Rs 267 crore, up 230% YoY
  • EBITDA margin of 24.3%, and PAT margin of 19.5%
  • Diluted EPS of Rs 11.7, up by 65% YoY (FV Re.1)

FY24 Financial Highlights:

  • Revenue from Operations at Rs 10,335 crore, up by 18%
  • Domestic revenue at Rs 9,522 crore, up by 13%; Exports at Rs 813 crore, up by 175%
  • EBITDA margin of 24.7%, and PAT margin of 18.8%
  • Diluted EPS of Rs 47.7, up by 49% (FV Re.1)
  • Cash flow from operations of Rs 2,152 crore, up by 19%
  • Net cash balance of Rs 3,260 crore as on 31st March 2024

Rajeev Juneja – Vice Chairman & Managing Director said, “This year, we have achieved a revenue milestone of Rs 10,000 crore. and added 3 more brand families worth over Rs 100 crore raising the total to 23.

Our strong revenue growth of 18% with EBITDA and PAT margin of ~25% and ~19% respectively is supported by an increase in Chronic share to 36% and growth in Modern Trade of over 50%.

We have further strengthened our chronic product portfolio with strategic in-house launches coupled with in-licensing of products like Symbicort – a globally renowned inhaler from Astra Zeneca.

Multiple technology led business transformation projects implemented across functions to further enhance efficiency and productivity laying the foundation for our next phase of growth.”

Result PDF

View Other Company Results

Mankind Pharma Ltd shares SWOT Analysis

Strengths (8)

  • Company with high TTM EPS Growth
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (1)

  • Declining Revenue every quarter for the past 2 quarters

Opportunity (0)

Data not found

Threats (4)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 2,137.0
R2 2,159.6
R3 2,196.1
Pivot

2,100.40

S1 2,077.8
S2 2,041.3
S3 2,018.7
EMA SMA
2,172.5
2,207.5
2,158.2
2,007.7
2,193.4
2,246.9
2,190.5
2,010.4
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
BEIGE LIMITED Bulk Sell 2024-03-26 2124.71 5817874 NSE
BEIGE LIMITED Bulk Sell 2024-03-26 2120.31 5817873 NSE
NEW WORLD FUND INC Block Purchase 2024-02-08 2107.35 1766434 NSE
Name Category Shares
Sheetal Arora PROMOTER 4.81%
Puja Juneja PROMOTER 2.88%
Poonam Juneja PROMOTER 2.64%
Arjun Juneja PROMOTER 2.04%
Ramesh Juneja PROMOTER 1.71%
Rajeev Juneja PROMOTER 1.62%
Chanakya Juneja PROMOTER 0.97%
Eklavya Juneja PROMOTER 0.97%
Mishka Arora PROMOTER 0.74%
Ramesh Juneja Family Trust (Held in the name of Ramesh Juneja, Managing Trustee) PROMOTER 20.81%
Rajeev Juneja Family Trust (Held in the name of Rajeev Juneja, Managing Trustee) PROMOTER 19.95%
Prem Sheetal Family Trust (Held in the name of Arora Family Private Limited, Trustee) PROMOTER 15.42%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Mankind Pharma Ltd Stocks COMPARISON

Financials( in Cr) Mankind Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 2,113.45 1,464.75 1,478.85 4,383.40 1,056.95
% Change -0.04 -0.09 0.01 3.01 -0.15
Mcap Cr 84,662.27 351,442.59 119,397.47 116,365.68 106,353.90
Revenue TTM Cr 8,749.43 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 1,309.68 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 44.29 35.16 28.03 70.58 27.63
1 Year Return 54.54 51.25 54.65 26.04 106.42
ROCE 23.11 16.79 14.76 19.30 16.25
ROE 19.27 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 7,435.22 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 35,090.66 -22,978.04
LAST 3M 106,793.94 -34,010.07
LAST 6M 169,541.16 45,373.47
LAST 12M 268,709.66 125,819.23

Mankind Pharma Ltd Information

Stock PE (TTM)
44.29
Promoter Holding
74.88%
Book Value
233.7062
ROCE
23.11%
ROE
19.27%
Description
  • Mankind Pharma Ltd. was incorporated on July 3, 1991, as a Private Limited Company with the name "Mankind Pharma Private Limited", by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory. In 2004, the Company entered the chronic pharmaceutical segment with the launch of `Amlokind` tablets and `Glimestar` tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of `Lubistar Eye Drops` and `Tobastar Eye Drops`. In 2007, the Company entered the consumer healthcare segment with the launch of `Manforce` brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories. It entered into the business of animal healthcare segment and launched `Bandykind` and `Ceftiforce`. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009. It launched the brand, `Preganews` into the consumer healthcare segment in year, 2010. In 2012, it set up their first R&D centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh. In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company. In 2017, a new manufacturing facility got established in Sikkim. In 2019, the Company entered into female infertility business segment and launched `Dydroboon` tablets. In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched `Cilaheart` tablets and `Statpure` tablets in the market. It launched `Zukanorm` tablets for diabetes pharmaceuticals segment. Another new subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE got incorporated during the year 2021. It launched `Mlife` tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of `Trugaba-NT` tablets and `Prebris-MNT` tablets. In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of `Pangraf Capsules` and `Mycept` tablets. It entered into the business of oncology segment with the launch of injection `Pacliall`. It acquired `Daffy` and `Combihale` brands from Dr. Reddy`s Laboratories. The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022. The Company is planning to raise capital from Public by issuing 40,058,844 Equity Shares through Offer for Sale.

Registered Address

208 Okhla Industrial Estate, Phase-III, New Delhi, New Delhi, 110020

Tel : 91-11-47476600
Email : investors:mankindpharma.com
Website : http://www.mankindpharma.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543904
NSE Code : MANKIND
Book Closure Date (Month) :
BSE Group : B
ISIN : INE634S01028

FAQ’s on Mankind Pharma Ltd Shares

You can buy Mankind Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Mankind Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 28, 2024 03:24 PM the closing price of Mankind Pharma Ltd was Rs.2,113.45.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 28, 2024 03:24 PM, the market cap of Mankind Pharma Ltd stood at Rs. 84,662.27.

The latest PE ratio of Mankind Pharma Ltd as of May 28, 2024 03:24 PM is 44.29

The latest PB ratio of Mankind Pharma Ltd as of May 28, 2024 03:24 PM is 0.11

The 52-week high of Mankind Pharma Ltd share price is Rs. 2,490.00 while the 52-week low is Rs. 1,320.00

Download App

Download Our App

Play Store App Store
market app